Estrella Immunopharma, Inc. (ESLAW) shareholders
Close on Nov 13, 2026Market cap $22.36MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ESLAW | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Boothbay Fund Management, LLC | 189,899 | – | $197.50K | – | 0.00% |
| D. E. Shaw & Co., Inc. | 87,500 | – | $12.46K | – | 0.00% |
| Yakira Capital Management, Inc. | 46,285 | – | $6.02K | – | 0.00% |
| Whitebox Advisors LLC | 42,293 | – | $5.50K | – | 0.00% |
| Clear Street Group Inc. | 34,082 | – | $4.43K | – | 0.00% |
| Toronto Dominion Bank | 21,635 | – | $2.81K | – | 0.00% |
| Robertson Stephens Wealth Management, LLC | 12,000 | – | $12.48K | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|
| Q2 2026 | 7 | 0M | 0 / 0 | 0 / 0 | 0M | 0M |
| Q1 2026 | 8 | 0M | 0 / 1 | 2 / 1 | 0M | 0M |
| Q4 2025 | 9 | 1M | 1 / 0 | 1 / 3 | 0M | 0M |
| Q3 2025 | 12 | 1M | 2 / 0 | 1 / 1 | 0M | 0M |
| Q2 2025 | 12 | 1M | 2 / 1 | 1 / 0 | 0M | 0M |
| Q1 2025 | 10 | 1M | 1 / 1 | 1 / 2 | 0M | 0M |
| Q4 2024 | 11 | 1M | 0 / 1 | 3 / 2 | 0M | 0M |
| Q3 2024 | 13 | 1M | 1 / 1 | 2 / 2 | 0M | 0M |
| Q2 2024 | 14 | 1M | 2 / 1 | 1 / 1 | 0M | 0M |
| Q1 2024 | 13 | 1M | 0 / 1 | 0 / 0 | 0M | 0M |
| Q4 2023 | 13 | 1M | 12 / 0 | 0 / 0 | 1M | 0M |
| Q3 2023 | 1 | 0M | 1 / 0 | 0 / 0 | 0M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| Cynthia Pussinen | Chief Executive Officer, Director | – | Nov 4, 2026 |
| Cheng Liu | CEO, Director | 397,437 | Aug 26, 2026 |
| Jiandong Xu | Chief Financial Officer | 382,188 | Aug 25, 2026 |
| Dengyao Jia | Director | – | Oct 1, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Cheng Liu CEO, Director | Aug 25, 2026 | Option exercise | +100,000 | $0.82 | $82.00K | 397,437 |
| Jiandong Xu Chief Financial Officer | Aug 18, 2026 | Option exercise | +100,000 | $0.82 | $82.00K | 365,488 |
| Jiandong Xu Chief Financial Officer | Oct 7, 2025 | Buy | +1,000 | $1.33 | $1.33K | 265,488 |
| Jiandong Xu Chief Financial Officer | Sep 22, 2025 | Buy | +1,000 | $1.16 | $1.16K | 16,700 |
| Jiandong Xu Chief Financial Officer | Sep 11, 2025 | Buy | +100 | $1.04 | $104 | 264,588 |
| Jeffrey A. Altman 10% owner | Sep 29, 2023 | Other | −255,000 | $10.86 | $2.77M | 0 |
| Jianwei Li Co-Chief Executive Officer, Director, 10% owner | Mar 4, 2022 | Buy | +141,970 | $314700.00 | $44.68B | 1,253,730 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Estrella Immunopharma's stock actually held short. No settlement fails above the SEC's reporting threshold in the last 90 days.
See a number that looks wrong?